FIGURE

Figure 9

ID

ZDB-FIG-230430-49

Publication

Cho et al., 2023 - CIGB-258 Exerts Potent Anti-Inflammatory Activity against Carboxymethyllysine-Induced Acute Inflammation in Hyperlipidemic Zebrafish via the Protection of Apolipoprotein A-I

Other Figures

All Figure Page

Back to All Figure Page

Figure 9

Comparison of the swimming ability and survivability after an intraperitoneal injection of carboxymethyllysine (CML) with Infliximab (Remsima), Etanercept (Enbrel), Tocilizumab (Actemra), or CIGB-258 (Jusvinza). (A) Still image of the swimming pattern of zebrafish 30 min and 120 min post-injection of CML with Infliximab (Remsima), Etanercept (Enbrel), Tocilizumab (Actemra), or CIGB-258 (Jusvinza) 30 min and 120 min post-injection. (B) Survivability of the zebrafish at 180 min post-injection of CML with Infliximab (Remsima), Etanercept (Enbrel), Tocilizumab (Actemra), or CIGB-258 (Jusvinza). *, p < 0.05 versus CML + PBS; ***, p < 0.001 versus CML + PBS. (C) Percentage of swimming zebrafish after an injection of CML with Infliximab (Remsima), Etanercept (Enbrel), Tocilizumab (Actemra), or CIGB-258 (Jusvinza) at 30 min, 60 min, and 120 min post-injection. *, p < 0.05 versus CML + PBS; ***, p < 0.001 versus CML + PBS.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Int. J. Mol. Sci.